Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma

Table 1 General information of the patients with hepatic metastatic melanoma

Case	Age (yr)	Gender	Primary melanoma lesion	Interval time before hepatic metastasis (yr)	Accompanying metastasis	Treatments	Survival time (mo)
1	39	M	Sclerotica	7	Spleen	Hepatectomy + comprehensive treatment	30
2	49	M	Left choroid	16	None	Puncture and biopsy + BCG	4
3	51	F	Rectum	0	Abdominal cavity	Biopsy + supportive therapy	1.5
4	69	M	Right lower eyelid	11	Recurrence of carcinoma in situ; metastasis to right hip	Biopsy + supportive therapy	2
5	68	M	Nasal cavity	0.6	Bilateral lung, pleura and cervical lymph nodes	Biopsy + supportive therapy	1.5
6	61	F	Back	8	None	Hepatectomy + comprehensive treatment	29
7	70	F	Resctum	1.5	Recurrence of carcinoma in situ	Mile’s surgery	14
8	48	M	Right 5th dactylus	0.5	Recurrence of carcinoma in situ	Hepatectomy, resection of primary lesion + comprehensive treatment	33
9	74	M	Sole	9	Inguinal lymph nodes	Hepatectomy	18

Table 2 The characteristics on imaging of the hepatic metastatic melanoma

Case	Tumor location	Tumor size	B-ultrasound	Computed tomography
1	Right liver	4.3 cm × 3.3 cm × 3.1 cm	NA	NA
2	Multiple	5 mm-12 cm	Low echo	Low density
3	Multiple		NA	Low density
4	Left liver	2.4 cm × 2.5 cm	Low echo, with partially peripheral dense echo	NA
5	Right liver	6.4 cm × 5.0 cm	Low echo, with peripheral low-echo areola, and a bit of strip blood flow inside	Low density
6	Multiple	5 mm-3 cm	Low echo, with peripheral low echo areola	Low density, with higher density peripherally
7	Left liver	2.5 cm × 2.1 cm	Mid-dense echo	Low density, with nodular enhancement
8	Multiple	5 mm-2.6 cm	Low echo	NA
9	Right liver	10 cm × 8 cm	No echo, with septum, and hyperechoic lesion	Cystic mass, with mild enhancement

NA: Not available.